Skip to content

Stoke Therapeutics, Inc.

STOK

CIK 0001623526

← back to feed
Revenue (TTM)
$189.25M
+404.5% YoY Q1 Apr 2026
Net Income (TTM)
$1.05M
+92.3% YoY Q1 Apr 2026
EPS Diluted (TTM)
$0.06
+92.7% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
-6.6%
Q1 Apr 2026
Net Margin
0.6%
Q1 Apr 2026
Free Cash Flow (TTM)
$24.64M
Q1 Apr 2026
Cash
$155.66M
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
62.28M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings